Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.

In one aspect, the invention provides a method for treating a protein-containing surface, including applying to the surface a microcapsule suspension including droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet, the wall including the salt formed from at least one amphiphilic Lewis acid reactant or amphiphilic Lewis base reactant, and at least one corresponding Lewis base reactant or Lewis acid reactant.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.

A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan, a hydration promoter, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Described are encapsulated compositions comprising at least one core-shell microcapsule. The at least one core-shell microcapsule comprises a core comprising at least one benefit agent and a shell surrounding the core. The shell comprises a polyurea resin formed by reaction of at least one trifunctional isocyanate with at least one polyfunctional amine not being chitosan. The at least one trifunctional isocyanate is an adduct of an aliphatic triol with at least one araliphatic diisocyanate. The weight ratio between moieties of the polyurea resin, which are derived from the trifunctional isocyanate, and the core is between 0.09 and 0.30, preferably between 0.10 and 0.20, more preferably between 0.11 and 0.18. The shell additionally comprises chitosan. The present disclosure also relates to a method for preparing such encapsulated compositions and to their use to enhance the performance of a benefit agent in a consumer product.

The present disclosure pertains to the technical field of vitamin K2, and relates to a vitamin K2 microcapsule, a preparation method thereof, and use thereof in the manufacture of a medicament for preventing and treating cardiovascular and cerebrovascular diseases. The vitamin K2 microcapsule contains the following components by weight: 0.001 to 10 parts of vitamin K2, 5 to 30 parts of polyunsaturated fatty acid source, 0.1 to 10 parts of vitamin E-polyethylene glycol succinate, 50 to 95 parts of water-phase wall material and 0.01 to 10 parts of antioxidant, the polyunsaturated fatty acid source contains an ω-6 source and an ω-3 source, and the antioxidant is a water-phase antioxidant and/or an oil-phase antioxidant. The vitamin K2 microcapsule prepared by the method of the present disclosure has good water solubility, good stability and high bioavailability, can significantly improve the preventive and/or therapeutic effects on cardiovascular and cerebrovascular diseases, and has broad application prospects.